LTRN
FDA on the calendar
Lantern Pharma isn’t getting a green light just yet, but it is getting something almost as important in biotech: a seat at the FDA table. The company said it has a Type C meeting planned for mid-May 2026 to discuss proposed tweaks to its Phase 2 HARMONIC trial of LP-300 in non-small cell lung cancer.
Why this matters
Clinical trials are basically a long game of “please don’t make us start over.” A regulatory meeting like this can help Lantern make sure its trial changes are aligned with what the FDA actually wants to see, which can reduce the odds of messy delays later.
The investor angle
If the agency is receptive, Lantern could get more confidence around the path forward for LP-300. If not, the stock may have to absorb another round of biotech-calendar drama — the kind where timelines move around like a group chat planning dinner.
Big picture: this is not a result yet, but it is a meaningful checkpoint. In biotech, paperwork and positioning can move a stock almost as much as data, because every step toward a cleaner regulatory path is another step toward the finish line.